71
Views
0
CrossRef citations to date
0
Altmetric
CASE SERIES

Case Study: Rosai-Dorfman Disease and Its Multifaceted Aspects

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 123-128 | Received 16 Oct 2023, Accepted 15 Feb 2024, Published online: 11 Mar 2024

References

  • Bruce-Brand C, Schneider JW, Schubert P. Rosai-Dorfman disease: an overview. J Clin Pathol. 2020;73(11):697–705. PMID: 32591351. doi:10.1136/jclinpath-2020-206733
  • Destombes P. Adenitis with lipid excess, in children or young adults, seen in the Antilles and in Mali. (4 cases). Bull Soc Pathol Exot Filiales. 1965;58(6):1169–1175.
  • Rosai J, Dorfman RF. Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological entity. Arch Pathol. 1969;87(1):63–70.
  • Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127(22):2672–2681. doi:10.1182/blood-2016-01-690636
  • Abla O, Jacobsen E, Picarsic J, et al. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood. 2018;131(26):2877–2890. doi:10.1182/blood-2018-03-839753
  • Garces S, Medeiros LJ, Patel KP, et al. Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai–Dorfman disease. Modern Pathol. 2017;30(10):1367–1377. doi:10.1038/modpathol.2017.55
  • Durham BH, Lopez Rodrigo E, Picarsic J. Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nature Med. 2019;25(12):1839–1842. doi:10.1038/s41591-019-0653-6
  • Diamond EL, Durham BH, Haroche J, et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov. 2016;6(2):154–165. doi:10.1158/2159-8290.CD-15-0913
  • Goyal G, Ravindran A, Young JR, et al. Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. Haematologica. 2020;105(2):348–357. doi:10.3324/haematol.2019.219626
  • Albano D, Bosio G, Bertagna F. 18F-FDG PET/CT Follow-up of Rosai-Dorfman disease. Clin Nucl Med. 2015;40(8):e420–e422. doi:10.1097/RLU.0000000000000853
  • Ahmed A, Crowson N, Magro CM. A comprehensive assessment of cutaneous Rosai-Dorfman disease. Ann Diagn Pathol. 2019;40:166–173. doi:10.1016/j.anndiagpath.2019.02.004
  • Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity. Semin Diagn Pathol. 1984;7:19–73.
  • Pulsoni A, Anghel G, Falcucci P, et al. Treatment of sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): report of a case and literature review. Am J Hematol. 2002;69(1):67–71. PMID: 11835335. doi:10.1002/ajh.10008
  • Lauwers GY, Perez-Atayde A, Dorfman RF, et al. The digestive system manifestations of Rosai-Dorfman disease (sinus histiocytosis with massive lymphadenopathy): review of 11 cases. Hum Pathol. 2000;31(3):380–385. doi:10.1016/s0046-8177(00)80254-3